当前位置: 首页 >> 检索结果
221. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
作者: Bruce E Sands.;Seymour Katz.;Douglas C Wolf.;Brian G Feagan.;Tao Wang.;Lisa-Marie Gustofson.;Cindy Wong.;Margaret K Vandervoort.;Stephen Hanauer.
来源: Gut. 2013年62卷9期1288-94页
Activated granulocytes and monocytes may contribute to the pathogenesis of Crohn's disease (CD). In small, uncontrolled studies, granulocyte/monocyte apheresis (GMA) has shown promise in treating CD. We conducted a randomised, double-blind study to compare GMA with a sham procedure in patients with moderate to severe CD.
222. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
作者: Nicholas J Shaheen.;Hans Denison.;Karin Björck.;Maria Karlsson.;Debra G Silberg.
来源: Gut. 2013年62卷9期1248-55页
Lesogaberan (AZD3355) is a novel γ-aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower oesophageal sphincter relaxations. A randomised, double-blind, placebo-controlled, multi-centre phase IIb study was performed to assess the efficacy and safety of lesogaberan as an add-on to proton pump inhibitor (PPI) therapy in patients with GERD who are partially responsive to PPI therapy (ClinicalTrials.gov reference: NCT01005251).
223. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
作者: Paul J Rutgeerts.;Richard N Fedorak.;Daan W Hommes.;Andreas Sturm.;Daniel C Baumgart.;Brian Bressler.;Stefan Schreiber.;John C Mansfield.;Marna Williams.;Meina Tang.;Jennifer Visich.;Xiaohui Wei.;Mary Keir.;Diana Luca.;Dimitri Danilenko.;Jackson Egen.;Sharon O'Byrne.
来源: Gut. 2013年62卷8期1122-30页
Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC.
224. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation.
作者: Adil E Bharucha.;Phillip Low.;Michael Camilleri.;Erica Veil.;Duane Burton.;Yogish Kudva.;Pankaj Shah.;Tonette Gehrking.;Alan R Zinsmeister.
来源: Gut. 2013年62卷5期708-15页
Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors increase colonic motility. This study evaluated the effects of a cholinesterase inhibitor on gastrointestinal and colonic transit and bowel function in diabetic patients with constipation.
225. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.
作者: Daniel Leffler.;Detlef Schuppan.;Kumar Pallav.;Robert Najarian.;Jeffery D Goldsmith.;Joshua Hansen.;Toufic Kabbani.;Melinda Dennis.;Ciarán P Kelly.
来源: Gut. 2013年62卷7期996-1004页
Coeliac disease is defined by gluten responsiveness, yet there are few data on gluten challenge (GC) in adults on a gluten-free diet. Lack of data regarding the kinetics of responses to gluten is a limitation in clinical practice and research when GC is performed.
226. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
作者: Wolfgang Hueber.;Bruce E Sands.;Steve Lewitzky.;Marc Vandemeulebroecke.;Walter Reinisch.;Peter D R Higgins.;Jan Wehkamp.;Brian G Feagan.;Michael D Yao.;Marek Karczewski.;Jacek Karczewski.;Nicole Pezous.;Stephan Bek.;Gerard Bruin.;Bjoern Mellgard.;Claudia Berger.;Marco Londei.;Arthur P Bertolino.;Gervais Tougas.;Simon P L Travis.; .
来源: Gut. 2012年61卷12期1693-700页
The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease.
227. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
作者: Lawrence Serfaty.;Xavier Forns.;Tobias Goeser.;Peter Ferenci.;Frederik Nevens.;Giampiero Carosi.;Joost P Drenth.;Isabelle Lonjon-Domanec.;Ralph DeMasi.;Gaston Picchio.;Maria Beumont.;Patrick Marcellin.
来源: Gut. 2012年61卷10期1473-80页
Insulin resistance is a predictor of poor response to peginterferon/ribavirin in patients infected with the chronic hepatitis C virus (HCV). There are no data on direct-acting antivirals. This exploratory analysis assessed the effect of metabolic factors and insulin resistance, measured by homoeostatic model assessment (HOMA), on virological response to telaprevir in Study C208.
228. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial.
作者: Prateek Sharma.;Robert H Hawes.;Ajay Bansal.;Neil Gupta.;Wouter Curvers.;Amit Rastogi.;Mandeep Singh.;Matt Hall.;Sharad C Mathur.;Sachin B Wani.;Brenda Hoffman.;Srinivas Gaddam.;Paul Fockens.;Jacques J Bergman.
来源: Gut. 2013年62卷1期15-21页
White light endoscopy with random biopsies is the standard for detection of intestinal metaplasia (IM) and neoplasia in patients with Barrett's oesophagus (BO). Narrow band imaging (NBI) highlights surface patterns that correlate with IM and neoplasia in BO.
229. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period.
作者: W O Rohof.;R J Bennink.;A A de Ruigh.;D P Hirsch.;A H Zwinderman.;G E Boeckxstaens.
来源: Gut. 2012年61卷12期1670-7页
The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. It was hypothesised that compounds affecting proximal stomach tone might reduce gastro-oesophageal reflux by changing the acid pocket position.
230. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial.
作者: Thomas R de Wijkerslooth.;Margriet C de Haan.;Esther M Stoop.;Patrick M Bossuyt.;Maarten Thomeer.;Marie-Louise Essink-Bot.;Monique E van Leerdam.;Paul Fockens.;Ernst J Kuipers.;Jaap Stoker.;Evelien Dekker.
来源: Gut. 2012年61卷11期1552-9页
CT-colonography has been suggested to be less burdensome for primary colorectal cancer (CRC) screening than colonoscopy. To compare the expected and perceived burden of both in a randomised trial.
231. Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial.
作者: Thomas R de Wijkerslooth.;Esther M Stoop.;Patrick M Bossuyt.;Elisabeth M H Mathus-Vliegen.;Jan Dees.;Kristien M A J Tytgat.;Monique E van Leerdam.;Paul Fockens.;Ernst J Kuipers.;Evelien Dekker.
来源: Gut. 2012年61卷10期1426-34页
Conventional colonoscopy (CC) is considered the reference standard for detection of colorectal neoplasia, but it can still miss a substantial number of adenomas. The use of a transparent plastic cap may improve colonic visualisation. Cap-assisted colonoscopy (CAC) was compared with CC for adenoma detection. Secondary outcomes were caecal intubation time, caecal intubation rate and the degree of discomfort of colonoscopy.
232. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial.
233. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells.
作者: Patrycja Konieczna.;David Groeger.;Mario Ziegler.;Remo Frei.;Ruth Ferstl.;Fergus Shanahan.;Eamonn M M Quigley.;Barry Kiely.;Cezmi A Akdis.;Liam O'Mahony.
来源: Gut. 2012年61卷3期354-66页
Intestinal homoeostasis is dependent on immunological tolerance to the microbiota.
234. Learners favour high resolution oesophageal manometry with better diagnostic accuracy over conventional line tracings.
High resolution manometry (HRM) provides a colourful representation of oesophageal motility. Novice and intermediate learners were tested to compare HRM Clouse plots and conventional manometry for accuracy, ease of interpretation and knowledge retention.
235. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial.
作者: Amit Rastogi.;Ajay Bansal.;Deepthi S Rao.;Neil Gupta.;Sachin B Wani.;Tracy Shipe.;Srinivas Gaddam.;Vikas Singh.;Prateek Sharma.
来源: Gut. 2012年61卷3期402-8页
Cap-assisted colonoscopy (CAC) uses a small plastic transparent cap attached to the tip of the colonoscope that can depress and flatten colonic folds and thus improve visualisation of their proximal aspects. The aim of this study was to compare CAC with standard colonoscopy (SC; high-definition white light) for adenoma detection rates.
236. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
作者: Cesare Hassan.;Douglas K Rex.;Gregory S Cooper.;Angelo Zullo.;Robert Launois.;Robert Benamouzig.
来源: Gut. 2012年61卷8期1172-9页
Low-dose aspirin reduces colorectal cancer (CRC) incidence and mortality. Recently, the aspirin effect has been shown to occur primarily in the proximal colon. Colonoscopy has been either less effective or ineffective in the proximal compared to the distal colon. The authors assessed the cost-effectiveness of adding low-dose aspirin to a simulated screening with colonoscopy or sigmoidoscopy.
237. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
作者: Gert Van Assche.;Séverine Vermeire.;Vera Ballet.;Frederik Gabriels.;Maja Noman.;Geert D'Haens.;Christophe Claessens.;Evelien Humblet.;Niels Vande Casteele.;Ann Gils.;Paul Rutgeerts.
来源: Gut. 2012年61卷2期229-34页
Elective switching between anti-tumour necrosis factor (TNF) agents not necessarily dictated by efficacy or tolerability occurs in clinical practice. A study was undertaken to evaluate prospectively the impact of elective switching of patients with Crohn's disease well controlled with intravenous infliximab to subcutaneous adalimumab in a controlled trial.
238. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
作者: Benjamin C Y Wong.;Lian Zhang.;Jun-ling Ma.;Kai-feng Pan.;Ji-you Li.;Lin Shen.;Wei-dong Liu.;Guo-shuang Feng.;Xiao-dong Zhang.;Jie Li.;Ai-ping Lu.;Harry H X Xia.;Shiukum Lam.;Wei-cheng You.
来源: Gut. 2012年61卷6期812-8页
Helicobacter pylori infection and overexpression of cyclo-oxygenase-2 (COX-2) are associated with gastric cancer and its precursors. To evaluate the effect of a selective COX-2 inhibitor alone and combined with H pylori eradication on the evolution of precancerous gastric lesions, a randomised, placebo-controlled trial was conducted in Linqu County, Shandong Province, China.
239. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
作者: Robert Benamouzig.;Bernard Uzzan.;Jacques Deyra.;Antoine Martin.;Bernard Girard.;Julian Little.;Stanislas Chaussade.; .
来源: Gut. 2012年61卷2期255-61页
Aspirin inhibits colorectal carcinogenesis. In a randomised double-blind placebo-controlled trial, daily soluble aspirin significantly reduced recurrence of colorectal adenomas at 1-year follow-up. In this study the results of daily intake of low-dose aspirin on polyp recurrence at 4-year follow-up are presented.
240. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
作者: Florence Wong.;Hugh Watson.;Alexander Gerbes.;Hendrik Vilstrup.;Salvatore Badalamenti.;Mauro Bernardi.;Pere Ginès.; .
来源: Gut. 2012年61卷1期108-16页
Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites.
|